Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNFerade with Chemoradiotherapy for Recurrent Head and Neck Cancer
NCT00496535Phase 2Completed
- Sponsor
- GenVec
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of golnerminogene pradenovec in head and neck cancer (HNC), sponsored by GenVec. Status: completed.
02
Drugs
golnerminogene pradenovec
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00496535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00496535.